Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system

Overview of attention for article published in BMC Pharmacology and Toxicology, September 2020

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 66 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 22 publications that cite this research output.

22

The most recent citing publications are shown below. View all 22 publications that cite this research output on Dimensions.

Comprehensive safety profile of dipeptidyl peptidase-4 inhibitors: a post-marketing study based on FAERS database using signal detection algorithms

Article in Expert Opinion on Drug Safety (April 2024)

A comprehensive review on potential drug–drug interactions of proton pump inhibitors with antidiabetic drugs metformin and DPP‐4 inhibitors

Article in Cell Biochemistry and Function (March 2024)

Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis

Article in Endocrinology and Metabolism (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.